AZD5438 in Patients With Advanced Solid Malignancies

This study has been completed.

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00088790

Purpose

Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.

Condition	Intervention	Phase
Neoplasms	Drug: AZD5438	Phase I

MedlinePlus related topics: Cancer

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Phase I Study to Assess the Safety and Tolerability of AZD5438 in Patients With Advanced Solid Malignancies

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Advanced solid malignancy
Cancer refractory to standard treatments or for which no standard therapy exits

Exclusion Criteria:

Radiotherapy within 3 weeks of the start of treatment
Investigational product within the last 3 weeks
Systemic cytotoxic anti-cancer therapy within the last 3 weeks
Any significant clinical disorder that makes it undesirable for the patient to participate

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00088790

Locations

United States, Massachusetts
Research Site
Boston, Massachusetts, United States
United States, New York
Research Site
New York City, New York, United States

Sponsors and Collaborators

AstraZeneca

More Information

Study ID Numbers:	D0110C00005
Study First Received:	August 4, 2004
Last Updated:	April 14, 2008
ClinicalTrials.gov Identifier:	NCT00088790
Health Authority:	United States: Food and Drug Administration

Keywords provided by AstraZeneca:

advanced, solid, malignancies

Additional relevant MeSH terms:

Neoplasms

ClinicalTrials.gov processed this record on January 14, 2009